KR102486047B1 - 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물 - Google Patents

근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물 Download PDF

Info

Publication number
KR102486047B1
KR102486047B1 KR1020200174844A KR20200174844A KR102486047B1 KR 102486047 B1 KR102486047 B1 KR 102486047B1 KR 1020200174844 A KR1020200174844 A KR 1020200174844A KR 20200174844 A KR20200174844 A KR 20200174844A KR 102486047 B1 KR102486047 B1 KR 102486047B1
Authority
KR
South Korea
Prior art keywords
muscle
gly
ser
leu
ala
Prior art date
Application number
KR1020200174844A
Other languages
English (en)
Korean (ko)
Other versions
KR20220084898A (ko
Inventor
최봉근
이성권
Original Assignee
주식회사 뉴온바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 뉴온바이오 filed Critical 주식회사 뉴온바이오
Priority to KR1020200174844A priority Critical patent/KR102486047B1/ko
Priority to PCT/KR2021/018973 priority patent/WO2022131750A1/fr
Publication of KR20220084898A publication Critical patent/KR20220084898A/ko
Application granted granted Critical
Publication of KR102486047B1 publication Critical patent/KR102486047B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020200174844A 2020-12-14 2020-12-14 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물 KR102486047B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020200174844A KR102486047B1 (ko) 2020-12-14 2020-12-14 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물
PCT/KR2021/018973 WO2022131750A1 (fr) 2020-12-14 2021-12-14 Composition pour le traitement ou la prévention de la myopathie, de l'obésité ou du diabète

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200174844A KR102486047B1 (ko) 2020-12-14 2020-12-14 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물

Publications (2)

Publication Number Publication Date
KR20220084898A KR20220084898A (ko) 2022-06-21
KR102486047B1 true KR102486047B1 (ko) 2023-01-11

Family

ID=82059316

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200174844A KR102486047B1 (ko) 2020-12-14 2020-12-14 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물

Country Status (2)

Country Link
KR (1) KR102486047B1 (fr)
WO (1) WO2022131750A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180140684A1 (en) 2012-11-15 2018-05-24 The Board Of Trustees Of The Leland Stanford Junior University Modulation of muscle and adipocyte distribution and fate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055643A1 (fr) * 1997-06-03 1998-12-10 Kureha Chemical Industry Co., Ltd. Proteine adamts-1 humaine, gene codant pour cette proteine, composition pharmaceutique et procede de dosage immunologique de proteine adamts-1 humaine
EP1136547A3 (fr) * 2000-03-22 2002-09-25 Pfizer Products Inc. Polypeptides Adamts, acides nucléiques codant pour ces polypeptides et leurs utilisations
WO2007147497A2 (fr) * 2006-06-17 2007-12-27 Bayer Healthcare Ag Utilisation d'un domaine du type désintégrine et métalloprotéinase à motif de thrombospondine de type 1 (adamts1) comme cible thérapeutique et diagnostique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180140684A1 (en) 2012-11-15 2018-05-24 The Board Of Trustees Of The Leland Stanford Junior University Modulation of muscle and adipocyte distribution and fate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pharmacogenetics and genomics, 2010, Vol.20, pp.766-774

Also Published As

Publication number Publication date
WO2022131750A1 (fr) 2022-06-23
KR20220084898A (ko) 2022-06-21

Similar Documents

Publication Publication Date Title
JP4487376B2 (ja) 腎疾患治療剤
US11040072B2 (en) Composition for inducing beige adipocyte differentiation containing exosome derived from stem cells
KR101966117B1 (ko) 가공인삼추출물을 포함하는 근육 분화 촉진용 조성물
CA2229479C (fr) Procede de stimulation de l'angiogenese
EP2937088B1 (fr) Composition présentant une activité de réparation tissulaire et son utilisation
KR20070109004A (ko) 오미자 추출물을 포함하는 골대사질환, 산화적 스트레스에의한 질환, 염증성질환의 예방과 치료용 약학조성물
WO2013044511A1 (fr) Composition pharmaceutique contenant du riligustilide et utilisation associée
JP2004529916A (ja) パーキンソン病の治療において神経栄養活性化合物と組み合わせたアデノシンａ２ａレセプターアンタゴニスト
KR102174191B1 (ko) 조직 재생 및 저하된 조직 기능의 회복을 자극하기 위한 제제로서의 디카르복시산의 비스아미드 유도체
KR102486047B1 (ko) 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물
KR102486046B1 (ko) 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물
US20080300182A1 (en) Eye disease treating agent and method for treating eye disease
KR102042084B1 (ko) 에스트라디올 전처리에 의해 생존율이 향상된 줄기세포와 그 제조방법, 및 이를 포함하는 당뇨병 및 이와 관련된 질병의 예방 또는 치료를 위한 세포치료제 조성물
KR20150071932A (ko) Taz 단백질 활성화 유도 성분을 포함하는 근육 분화 및 근육재생용 약학적 조성물
KR102076777B1 (ko) Gas6 단백질 또는 이의 수용체 활성화제를 포함하는 섬유증의 예방 또는 치료용 조성물
EP4378468A1 (fr) Composition pour le traitement de maladies liées à la perte musculaire comprenant des exosomes dérivés de cellules souches mésenchymateuses de l'amygdale
TWI818286B (zh) 包括表現腫瘤壞死因子可誘導基因６的間葉幹細胞之組成物及藥物組成物
KR20210116350A (ko) 심장줄기세포를 포함하는 허혈성 질환의 예방 또는 치료용 조성물
KR20210020818A (ko) 초과 추출물을 함유하는 근육 감소 관련 질병의 예방, 개선, 또는 치료용 조성물
KR20110105439A (ko) 항비만 또는 체지방감소를 위한 조성물
CN117442603B (zh) 夏佛塔苷在制备抗心力衰竭药物中的应用
WO2024122720A1 (fr) Peptide pour régénérer le cartilage et ses utilisations
Andersson et al. Release of endothelin-1 into rat airways following Sephadex-induced inflammation; modulation by enzyme inhibitors and budesonide
WO2024122721A1 (fr) Peptide pour régénérer le cartilage et ses utilisations
WO2024122726A1 (fr) Peptide pour la régénération du cartilage et ses utilisations

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right